197 related articles for article (PubMed ID: 15329909)
21. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).
Rodig SJ; Abramson JS; Pinkus GS; Treon SP; Dorfman DM; Dong HY; Shipp MA; Kutok JL
Clin Cancer Res; 2006 Dec; 12(23):7174-9. PubMed ID: 17145843
[TBL] [Abstract][Full Text] [Related]
22. Monoclonal antibodies in the treatment of chronic lymphoid leukemias.
Robak T
Leuk Lymphoma; 2004 Feb; 45(2):205-19. PubMed ID: 15101704
[TBL] [Abstract][Full Text] [Related]
23. Alemtuzumab in CLL and other lymphoid neoplasms.
Ravandi F; O'brien S
Cancer Invest; 2006 Nov; 24(7):718-25. PubMed ID: 17118783
[TBL] [Abstract][Full Text] [Related]
24. Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody).
Karlsson C; Hansson L; Celsing F; Lundin J
Leukemia; 2007 Mar; 21(3):511-4. PubMed ID: 17215854
[TBL] [Abstract][Full Text] [Related]
25. A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.
Lapalombella R; Zhao X; Triantafillou G; Yu B; Jin Y; Lozanski G; Cheney C; Heerema N; Jarjoura D; Lehman A; Lee LJ; Marcucci G; Lee RJ; Caligiuri MA; Muthusamy N; Byrd JC
Clin Cancer Res; 2008 Jan; 14(2):569-78. PubMed ID: 18223233
[TBL] [Abstract][Full Text] [Related]
26. Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models.
Siders WM; Shields J; Garron C; Hu Y; Boutin P; Shankara S; Weber W; Roberts B; Kaplan JM
Leuk Lymphoma; 2010 Jul; 51(7):1293-304. PubMed ID: 20377308
[TBL] [Abstract][Full Text] [Related]
27. Effect of alemtuzumab on neoplastic B cells.
Golay J; Manganini M; Rambaldi A; Introna M
Haematologica; 2004 Dec; 89(12):1476-83. PubMed ID: 15590398
[TBL] [Abstract][Full Text] [Related]
28. Activity of alemtuzumab in patients with CD52-positive acute leukemia.
Tibes R; Keating MJ; Ferrajoli A; Wierda W; Ravandi F; Garcia-Manero G; O'Brien S; Cortes J; Verstovsek S; Browning ML; Faderl S
Cancer; 2006 Jun; 106(12):2645-51. PubMed ID: 16688777
[TBL] [Abstract][Full Text] [Related]
29. Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR).
Alatrash G; Albitar M; O'Brien S; Wang X; Manshouri T; Faderl S; Ferrajoli A; Burger J; Garcia-Manero G; Kantarjian HM; Lerner S; Keating MJ; Wierda WG
Br J Haematol; 2010 Feb; 148(3):386-93. PubMed ID: 19895616
[TBL] [Abstract][Full Text] [Related]
30. Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901.
Byrd JC; Peterson BL; Rai KR; Hurd D; Hohl R; Perry MC; Gockerman J; Nattam S; Larson RA
Leuk Lymphoma; 2009 Oct; 50(10):1589-96. PubMed ID: 19863336
[TBL] [Abstract][Full Text] [Related]
31. Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism.
Mone AP; Cheney C; Banks AL; Tridandapani S; Mehter N; Guster S; Lin T; Eisenbeis CF; Young DC; Byrd JC
Leukemia; 2006 Feb; 20(2):272-9. PubMed ID: 16341049
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of alemtuzumab after haploidentical HLA-mismatched hematopoietic stem cell transplantation using in vivo alemtuzumab with or without CD52-positive malignancies.
Oshima K; Kanda Y; Nakahara F; Shoda E; Suzuki T; Imai Y; Watanabe T; Asai T; Izutsu K; Ogawa S; Motokura T; Chiba S; Kurokawa M
Am J Hematol; 2006 Nov; 81(11):875-9. PubMed ID: 16862551
[TBL] [Abstract][Full Text] [Related]
33. CD52 expression in Waldenstrom's macroglobulinemia: implications for alemtuzumab therapy and response assessment.
Owen RG; Hillmen P; Rawstron AC
Clin Lymphoma; 2005 Mar; 5(4):278-81. PubMed ID: 15794865
[TBL] [Abstract][Full Text] [Related]
34. Antimouse CD52 monoclonal antibody inhibits established spontaneous colitis in IL-10-deficient mice.
Zhu WM; Li Y; Yu C; Li N; Li JS
Inflamm Bowel Dis; 2011 Jul; 17(7):E72-3. PubMed ID: 21538714
[No Abstract] [Full Text] [Related]
35. Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy.
Jiang L; Yuan CM; Hubacheck J; Janik JE; Wilson W; Morris JC; Jasper GA; Stetler-Stevenson M
Br J Haematol; 2009 Apr; 145(2):173-9. PubMed ID: 19236377
[TBL] [Abstract][Full Text] [Related]
36. Emergence of CD52-, glycosylphosphatidylinositol-anchor-deficient lymphocytes in rheumatoid arthritis patients following Campath-1H treatment.
Brett SJ; Baxter G; Cooper H; Rowan W; Regan T; Tite J; Rapson N
Int Immunol; 1996 Mar; 8(3):325-34. PubMed ID: 8671618
[TBL] [Abstract][Full Text] [Related]
37. Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies.
Robak T
Transfus Apher Sci; 2005 Feb; 32(1):33-44. PubMed ID: 15737872
[TBL] [Abstract][Full Text] [Related]
38. Alemtuzumab in the treatment of chronic lymphocytic lymphoma.
Boyd K; Dearden CE
Expert Rev Anticancer Ther; 2008 Apr; 8(4):525-33. PubMed ID: 18402519
[TBL] [Abstract][Full Text] [Related]
39. Clinical effects of alemtuzumab (Campath-1H) in B-cell chronic lymphocytic leukemia.
Osterborg A; Mellstedt H; Keating M
Med Oncol; 2002; 19 Suppl():S21-6. PubMed ID: 12180488
[TBL] [Abstract][Full Text] [Related]
40. Targeting CD52 as a novel therapeutic strategy in angioimmunoblastic T-cell lymphoma.
Dunleavy K; Wilson WH
Leuk Lymphoma; 2010 Sep; 51(9):1583-4. PubMed ID: 20795788
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
